Keyword: Pandion Therapeutics
Pandion and Astellas inked a deal to discover, develop and market bispecific drugs for Type 1 diabetes and other autoimmune diseases of the pancreas.
Gilead continues revamp with 3 more exec exits; GSK snares ex-Novartis, AZ CFO as chairman; and Immusoft names former Amgen biologics head as CSO.
This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.
Reverse engineering localized antibodies that protect organs from inflammatory and autoimmune diseases by mimicking tumors.
All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors.